共 129 条
[1]
Ferlay J(2013)Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012 Eur J Cancer. 49 1374-1403
[2]
Steliarova-Foucher E(2018)Changes in ovarian cancer survival during the 20 years before the era of targeted therapy BMC Cancer. 18 601-1939
[3]
Lortet-Tieulent J(2019)Secondary surgical cytoreduction for recurrent ovarian cancer N Engl J Med. 381 1929-1995
[4]
Rosso S(2014)A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer Ann Oncol. 25 1988-442
[5]
Coebergh JWW(2007)Targeting the mTOR signaling network in cancer Trends Mol Med. 13 433-7681
[6]
Comber H(2004)Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res. 64 7678-1078
[7]
Forman D(2014)PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer Arch Gynecol Obstet. 290 1067-920
[8]
Bray F(2007)Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma Int J Cancer. 121 915-247
[9]
Lee J-Y(2020)Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer J Clin Oncol 38 3604-423
[10]
Kim S(2020)Randomized phase II study of sapanisertib (SAP) + paclitaxel (PAC) plus PAC alone in patients (pts) with advanced, recurrent or persistent endometrial cancer J Clin Oncol 38 6087-281